Ardelyx, Inc. is facing a securities fraud class-action lawsuit, with law firms reminding investors of the upcoming deadline to seek lead plaintiff status. The lawsuit alleges that the company made false and misleading statements regarding the commercial performance and growth prospects for its key drugs, XPHOZAH and IBSRELA. Specifically, it claims the company failed to disclose increasing barriers to patient access and reimbursement which were slowing new patient starts.
The legal action follows the company's announcement on August 6, 2026, where it reduced its full-year 2026 revenue guidance for IBSRELA and completely withdrew its long-term guidance for XPHOZAH, citing "evolving market dynamics." This news caused the stock price to decline significantly, falling approximately 18% on August 7, 2026.